Dr. Abhijit Bopardikar
Analysis of numerous clinical trial results in regenerative medicine generally shows low level of efficacy with stem cells due to which very few trials actually reach culmination. This is due to the fact that most researchers do not take into account the importance of stem cell microenvironments in the treatment design, use an insufficient number or type of stem cells, and/or ignore the possibility of using exosomes in the complex therapy of patients. Proliferation, differentiation and engraftment of stem cells (SCs) require a specific, pre-defined microenvironment called ‘stem cell niche’. For in vivo modulation of organ-specific niches during SCs transplantation, appropriate tissue based growth factors (including Placental tissue extracts - PTEs and Fetal Tissue extracts - FTEs) can improve outcomes significantly. Mesenchymal stem cell (MSC) and especially hematopoietic stem cell (HSC) culture, enumeration and amplification provide adequate number of cells for optimum results. Additionally growth factors and exosomes can induce the phenotypic modifications of SCs. We investigated the content of growth factors in FTEs and PTEs; studied the efficacy of adding these in patients who did not respond well to conventional SC treatment and optimized results considerably. We showed impact of PTEs/FTEs for remodeling the SC niche in treatment of liver cirrhosis and non-healing wounds and ulcers in patients.
English 
Spanish 
Chinese 
German 
French 
Japanese 
Portuguese 
Hindi